Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 112,779 | 172,921 | 217,597 | 101,788 | 165,007 |
| Marketable Securities | 533,281 | 483,714 | 376,031 | 223,128 | 178,019 |
| TOTAL | $652,470 | $661,386 | $599,796 | $335,269 | $354,506 |
| Non-Current Assets | |||||
| PPE Net | 32 | 38 | 7 | 22 | 38 |
| Other Non-Current Assets | 360 | 382 | 144 | 433 | 397 |
| TOTAL | $392 | $420 | $151 | $455 | $435 |
| Total Assets | $652,862 | $661,806 | $599,947 | $335,724 | $354,941 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,116 | 2,017 | 1,121 | 3,164 | 373 |
| Accrued Expenses | 13,602 | 13,096 | 22,399 | 19,009 | 13,013 |
| TOTAL | $14,718 | $15,113 | $23,520 | $22,173 | $13,386 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $14,718 | $15,113 | $23,520 | $22,173 | $13,386 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 82,498 | 82,399 | 79,140 | 66,295 | 65,175 |
| Common Shares | 8 | 8 | 8 | 6 | 6 |
| Retained earnings | -496,508 | -457,169 | -424,935 | -388,003 | -344,729 |
| TOTAL | $638,144 | $646,693 | $576,427 | $313,551 | $341,555 |
| Total Liabilities And Equity | $652,862 | $661,806 | $599,947 | $335,724 | $354,941 |